Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29636747 | 0.86 | HDAC1 (0.41) | HDAC1NAMPTGRIN2BGSK3BDYRK1A | |
| SCHEMBL28579578 | 0.86 | HDAC1 (0.41) | HDAC1NAMPTGRIN2BGSK3BDYRK1A | |
| SCHEMBL21375791 | 0.86 | HDAC1 (0.41) | HDAC1NAMPTGRIN2BGSK3BDYRK1A | |
| SCHEMBL479056 | 0.83 | NAMPT (0.43) | HDAC1NAMPTGRIN2BGSK3BDYRK1A | |
| SCHEMBL28849745 | 0.82 | NAMPT (0.42) | HDAC1NAMPTGRIN2BGSK3BDYRK1A | |
| SCHEMBL19398230 | 0.80 | RAB9A (0.45) | HDAC1NAMPTGRIN2BGSK3BDYRK1A | |
| SCHEMBL2307440 | 0.77 | GSK3B (0.44) | HDAC1NAMPTGRIN2BGSK3BDYRK1A | |
| SCHEMBL15701270 | 0.77 | NAMPT (0.48) | HDAC1NAMPTGRIN2BGSK3BDYRK1A | |
| SCHEMBL31737264 | 0.76 | GSK3B (0.45) | HDAC1NAMPTGRIN2BGSK3BDYRK1A | |
| SCHEMBL8228538 | 0.76 | DEGS1 (0.49) | HDAC1NAMPTGRIN2BGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300466-B1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8410128-B2 | Triazolopyridine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410128-B2 | Triazolopyridine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-8338604-B2 | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110288085-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-24 | — | — | US | disclosed |
| US-20110077243-A1 | Triazolopyridine Compounds Useful As Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
| WO-2009155389-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155388-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077243-A1 | Triazolopyridine Compounds Useful As Kinase Inhibitors | MAP3K1, MAP3K5, MAP3K8 | HDAC1 639/4885NAMPT 1689/4885GRIN2B 1092/4885 |
| US-20110288085-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP4K2, MAPKAPK2, MAP3K5 | HDAC1 264/4885NAMPT 1222/4885GRIN2B 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.